These courses are intended for internal hospital staff.

Activity Description:

The Tumor Board series consists of case presentations that are led by recognized multidisciplinary experts in the topic area. Multidisciplinary tumor boards bring together health care professionals from multiple specialties to strategize about the best treatments for rectal cancer cases. Please note that these tumor boards may only be accessed by qualified professionals directly associated with patient treatment. With the rapidly changing advances in the medical field, this is a forum that will provide clinical staff the opportunity to discuss and share new cutting-edge science, clinical, prognostic, biologic, Radiologic, and treatment information for all who attend.  For example, the incorporation of palliative care in the management of advanced stage patients is now a standard ASCO recommendation that will aid in the ongoing review of oncology patients.  Communication goals of therapy to patients is also a goal of modern cancer care, and this series will help providers in expressing these goals more clearly to their patients.  This series will also aid in decreasing the need to refer to the needed specialties for curbside consults which causes significant lag time and added effort to get real-time advice.

Target Audience: 

Anesthesiology, Diagnostic Radiology, Internal Medicine, Medical Genetics, Pathology, Physical Medicine & Rehabilitation, Surgery, Urology

Learning Objectives:

• Utilize multidisciplinary approaches to diagnosis and staging of patients with rectal cancer including the findings from imaging, biopsy and surgery, genetic and molecular studies
• Implement optimal treatment plans for the patients with cancer integrating surgery, radiation therapy, chemotherapy, targeted therapy and immunotherapy as needed
• Describe evidence and/or guideline-based approaches to therapy as well as available clinical trials
• Address the cultural, linguistic, ethnic, religious, and socio-economic barriers which may affect a given patient’s treatment

Moderator:

Michael Porter, MD

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies.*

*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.

Accreditation:

The HCA Healthcare Continental Division is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

Credit Designation:

The HCA Healthcare Continental Division designates this live activity for a maximum of 0.5 AMA PRA Category 1^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support:  

This Activity was developed without support from any ineligible company.*The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Note: The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical services is owned, or controlled by, and ACCME defined ineligible company.

Disclosure: 

The HCA Healthcare Continental Division is committed to providing CME that is balanced, objective, and evidenced-based. In accordance with the Accreditation Council for Continuing Medical Education Standards for Integrity and Independence all parties involved in content development are required to disclose all conflicts of interest with ACCME defined ineligible companies. The HCA Healthcare Continental Division has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity. The CME planning committee who are in a position to control the content of this CME Activity, have no relevant financial relationships with ineligible companies to disclose.